Will there be rapid growth once dabrafenib is discontinued? Analysis of treatment response after drug withdrawal

Dabrafenib is a BRAF inhibitor mainly used to treat advanced melanoma and non-small cell lung cancer carrying BRAF V600E mutations. It inhibits the growth of tumors by inhibiting abnormally activated BRAF proteins and blocking the proliferation signaling pathways of tumor cells. However, once the drug is stopped, some patients may experience "rebound progression" of tumors, that is, the lesions rapidly increase in size within a short period of time. This phenomenon is more common in targeted therapies.

This rapid growth phenomenon may be related to the "adaptive drug resistance" of tumor cells. During dabrafenib treatment, although some tumor cells were not completely killed, their activity was inhibited by the drug. Once the drug is discontinued, these remaining cells quickly rejuvenate in an environment lacking inhibition, and even promote tumor progression by activating alternative pathways (such as MEK, ERK, etc.), leading to short-term worsening of the disease. This also explains why it is clinically recommended to avoid unplanned discontinuation of medication.

Of course, not all patients will progress rapidly after stopping the drug. Some patients have tumors that grow slowly, or have been combined with MEK inhibitors (such as trametinib), which reduces the risk of drug resistance. However, if there is no alternative treatment when the drug is discontinued, some high-risk patients (such as those with large tumor burden and obvious drug resistance tendency) are more likely to have a rapid rebound in disease, so the risk needs to be assessed under the guidance of a doctor.

For patients who are considering discontinuing dabrafenib, it is usually recommended to make a comprehensive clinical judgment based on multiple factors, such as efficacy evaluation, disease stability, and whether there are serious adverse reactions. If the drug must be stopped, imaging review should be arranged promptly or other treatment options should be considered, such as chemotherapy, immunotherapy, or participation in clinical trials, to mitigate the risks caused by disease fluctuations. In summary, dabrafenib treatment requires careful management of the discontinuation process to ensure treatment continuity and patient safety.

Reference materials:https://go.drugbank.com/drugs/DB08912